History

History

Year Month Corporate History
2005 February Chiome Bioscience Inc. (capital: 10 million yen) was established in the Bunkyo district of Tokyo to commercialize the ADLib® system developed through the collaboration of the Genetic Dynamics Research Unit at RIKEN, headed by Dr. Kunihiro Ohta (currently serving as an Executive Director at Chiome Bioscience Inc.), and the Saitama Small and Medium Enterprise Development Corporation (currently Saitama Industrial Development Corporation).
April Chiome Bioscience Inc. concluded an agreement with RIKEN to commercialize the ADLib® system, and research activities begins.
May ADLib® System was described in the journal Nature Biotechnology as “an innovative rapid antibody generating technology to be the first in the world that employs promotion of DNA recombination.”
July CHIOME has obtained an exclusive license to commercialize platform technology (the ADLib® System) from RIKEN Institute and the Japanese Science and Technology Agency. And CHIOME can sublicense this technology to other third parties.
2008 May The R&D Division has relocated to RIKEN-WAKO Incubation Plaza to allow for the expansion of research facilities.
2009 October The head office has relocated to Shinjuku ward, Tokyo.
2010 August Chiome Bioscience Inc. concluded a payment based technology transfer agreement with the Japan Science and Technology Agency on the platform technology - the ADLib® System.
2011 December CHIOME is now listed on Tokyo Stock Exchange Mothers Index.
2013 May The head office has relocated to Shibuya ward, Tokyo.
December Chiome Bioscience Inc. acquired a majority of Liv Tech, Inc.'s capital.
2015 July Chiome Bioscience Inc. merged with Liv Tech, Inc.
October Chiome Bioscience Inc. executed an investment in capital of to EVEC, Inc.
2017 February Chiome Bioscience Inc. acquired new shares of Trans Chromosomics, Inc. issued in a third- party allotment.
September Chiome Bioscience Inc. executed a License Agreement with ADC Therapeutics SA for the development, manufacture, and commercialization of an ADC of LIV-1205.